Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration
Top Cited Papers
- 1 July 2010
- journal article
- research article
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 56 (2), 134-143
- https://doi.org/10.1016/j.jacc.2009.12.071
Abstract
No abstract availableKeywords
Funding Information
- Bristol-Myers Squibb
- Sanofi-Aventis
- Eli Lilly
- Guerbet Medical
- Medtronic
- Boston Scientific
- Cordis
- Stago
- Fondation de France
- Inserm
- Fédération Française de Cardiologie
- Société Française de Cardiologie
- Sanofi-Aventis
- Daiichi Sankyo
- Eli Lilly
- Inserm
- Fédération Française de Cardiologie
- Société Française de Cardiologie
- Sanofi-Aventis
- Fédération Française de Cardiologie
- Bristol-Myers Squibb
- Sanofi-Aventis
- Eli Lilly
- Guerbet Medical
- Medtronic
- Boston Scientific
- Cordis
- Stago
- Centocor
- Fondation de France
- Inserm
- Fédération Française de Cardiologie
- Société Française de Cardiologie
- ITC Edison
- Pfizer
This publication has 36 references indexed in Scilit:
- Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel TherapyJAMA, 2009
- A population-based study of the drug interaction between proton pump inhibitors and clopidogrelCMAJ : Canadian Medical Association Journal, 2009
- Relation of Cytochrome P450 2C19 Loss-of-Function Polymorphism to Occurrence of Drug-Eluting Coronary Stent ThrombosisThe American Journal of Cardiology, 2009
- Cytochrome P-450 Polymorphisms and Response to ClopidogrelNew England Journal of Medicine, 2009
- Genetic Determinants of Response to Clopidogrel and Cardiovascular EventsNew England Journal of Medicine, 2009
- Cardiovascular Death and Nonfatal Myocardial Infarction in Acute Coronary Syndrome Patients Receiving Coronary Stenting Are Predicted by Residual Platelet Reactivity to ADP Detected by a Point-of-Care AssayCirculation, 2009
- Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort studyThe Lancet, 2009
- Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary interventionEuropean Heart Journal, 2008
- Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and ClopidogrelThe Journal of Clinical Pharmacology, 2008
- Clopidogrel for Coronary StentingCirculation, 2003